- Market Capitalization, $K 417,702
- Shares Outstanding, K 103,648
- Annual Sales, $ 102,310 K
- Annual Income, $ 31,880 K
- 60-Month Beta 1.41
- Price/Sales 3.63
- Price/Cash Flow 12.86
- Price/Book 2.83
|Period||Period Low||Period High||Performance|
| || |
+0.43 (+11.94%)since 01/22/21
| || |
+0.55 (+15.80%)since 11/24/20
| || |
-0.88 (-17.92%)since 02/24/20
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating,...
The Robinhood app is popular among millennial investors. And as the Covid-19 pandemic focused attention on the biotech industry last year, many young investors rushed to bet on the sector. Though market...
Catalyst (CPRX) plans to expand its product portfolio beyond Firdapse.
-- Company to Expand R&D Focus for Pipeline Growth to include Earlier Stage Programs and Validated Technology Platforms
Catalyst Pharmaceuticals (CPRX) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Catalyst (CPRX) beats on earnings but misses sales estimates in the third quarter of 2020.
Catalyst (CPRX) delivered earnings and revenue surprises of 22.22% and -6.10%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
- Firdapse(R) Third Quarter Net Revenues of $29.2 Million
Catalyst (CPRX) will provide updates on earnings and revenues when its releases third-quarter 2020 results.
|Catalyst Pharm Inc|
|DJ Select Microcap First Trust|
|Hartford Multifactor Small Cap ETF|
|S&P Biotech SPDR|
|US Pharmaceuticals Ishares ETF|
|Ishares Factors US Small Blend Style ETF|